谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients

S. Merat,H. Poustchi,A-H Sharifi, A. Nateghi,E. Hajiani, A. Gharavi,M-H Somi,M-R Ghadir,H. Kalantari,F. Mansour-Ghanaei,J. Karimi,M-R Fattahi,N. Baniasadi, S. Moosavy, S-A Dehghan-Manshadi,M. Sofian,B. Sayad, P. Abazar,T. Amiriani,A. Bakhshipour,M. Mokhtare,A. Sharifian,M. Minakari,M. J. Zahedi,M. Sohrabi, M. Ghezloo,R. Jamali, S. M. V. Toosi, B. Afshar,I. Maleki,M. Ziaee,A. Hormati, F. R. Samani, L. Eslami,H. Fakheri, L. Goshayeshi, S. Sali,A. A. Sohrabpour,A. Norouzi, H. Sardarian,A. Janbakhsh, A. A. Shayesteh,L. Ahmadi, D. Merat, E. Shayesteh,R. Malekzadeh

JOURNAL OF VIRAL HEPATITIS（2018）

引用 0|浏览14
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要